Cargando…
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
BACKGROUND: Mifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains unclear whether the expression of PR is required for MF to act as an anti-cancer age...
Autores principales: | Tieszen, Chelsea R, Goyeneche, Alicia A, Brandhagen, BreeAnn N, Ortbahn, Casey T, Telleria, Carlos M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125282/ https://www.ncbi.nlm.nih.gov/pubmed/21619605 http://dx.doi.org/10.1186/1471-2407-11-207 |
Ejemplares similares
-
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics
por: Brandhagen, BreeAnn N, et al.
Publicado: (2013) -
Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling
por: Ritch, Sabrina J., et al.
Publicado: (2019) -
Antiprogestins in gynecological diseases
por: Goyeneche, Alicia A, et al.
Publicado: (2015) -
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014) -
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2
por: Goyeneche, Alicia A., et al.
Publicado: (2011)